@article{51682f3bfcae452997e559e4d360746c,
title = "Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?",
abstract = "[No abstract available]",
keywords = "peginterferon, ribavirin, alpha interferon, macrogol derivative, peginterferon alpha2a, recombinant protein, hepatitis C, Hepatitis C virus genotype 2, Hepatitis C virus genotype 3, human, Letter, outpatient department, polymerase chain reaction, priority journal, recurrence risk, treatment duration, adult, aged, case control study, drug administration, drug combination, drug effects, female, genetics, genotype, male, middle aged, prognosis, retrospective study, risk assessment, severity of illness index, time, treatment outcome, virus load, Adult, Aged, Case-Control Studies, Drug Administration Schedule, Drug Therapy, Combination, Female, Genotype, Hepatitis C, Humans, Interferon-alpha, Male, Middle Aged, Polyethylene Glycols, Prognosis, Recombinant Proteins, Retrospective Studies, Ribavirin, Risk Assessment, Severity of Illness Index, Time Factors, Treatment Outcome, Viral Load",
author = "Carla Silva and Elizabeth Ianna and Tracey Jones and Joshua Davis",
year = "2015",
month = aug,
doi = "10.1002/hep.27601",
language = "English",
volume = "62",
pages = "660--661",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley & Sons",
number = "2",
}
